Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
Want to see AU:PIQ full AI Analyst Report?
PIQ Stock Chart & Stats
AU$0.67
AU$0.03(4.23%)
At close: 4:00 PM EST
AU$0.67
AU$0.03(4.23%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.86
Previous CloseN/A
Volume90.30K
Average Volume (3M)426.90K
Market Cap
AU$17.76M
Enterprise ValueAU$14.49M
Total Cash (Recent Filing)AU$7.67M
Total Debt (Recent Filing)AU$681.45K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding165,197,510
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$4.30M
Bulls Say, Bears Say
Bulls Say
Low Leverage (minimal Debt)A debt-to-equity of 0.021 gives the company financial flexibility and lower insolvency risk over the medium term. With minimal interest burden, management can prioritize R&D and commercialization spending without near-term refinancing pressure, extending runway while pursuing adoption.
Proprietary Proteomics Diagnostic (DKD Test)Owning a differentiated, validated proteomics diagnostic (notably a blood test for diabetic kidney disease) is a structural competitive asset. If clinically adopted and reimbursed, it can generate recurring test volume, licensing opportunities and durable differentiation versus generic lab services.
Dual Revenue Model: Diagnostics And ServicesHaving both diagnostics sales and contract proteomics services diversifies cash generation. Services provide fee-for-service revenues and client relationships that can stabilize near-term inflows, while diagnostics offer higher scalability and margin potential if clinical adoption increases.
Bears Say
Steep Revenue ContractionA >70% revenue drop is a material structural weakness: it reduces scale, erodes distributor and payer confidence, and constrains investment in commercialization. Sustained declines make achieving operating leverage and clinical adoption targets much harder over the next several quarters.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows signal cash burn that will require external funding or cost cuts. This constrains sustained commercial roll-out, R&D programs and partnership execution, and increases dilution or restructuring risk if revenue recovery is slow.
Ongoing Unprofitability And Negative ROENegative margins and ROE indicate the business currently destroys shareholder capital. Even with positive gross margin, operating costs outpace revenues, limiting capacity to self-fund growth. Without margin improvement, long-term viability relies on sustained top-line recovery or structural cost changes.
Proteomics International Laboratories Ltd. News
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.10 and its highest was AU$0.86 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Proteomics International Laboratories Ltd.’s market cap is AU$17.76M.
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 65 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.04.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 165,197,510 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Proteomics International Laboratories Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.16%
12-Months-Change
Fundamentals
Return on Equity
-93.66%
Trailing 12-Months
Asset Growth
60.94%
Trailing 12-Months
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Pharmaust Limited
―
Chimeric Therapeutics Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---